Skip to main content

Table 2 Monoclonal antibody dosing regimen and dose flexibility

From: A review article of inflammatory bowel disease treatment and pharmacogenomics

Subcutaneous [12]. BIOLOGIC

Induction regimen

Maintenance dose

Maintenance interval

Escalation

Infliximab

5 mg at week 0

5 mg/kg

Q8

10 mg/kgQ8

OR 5 mg/kg Q4

Adalimumab

160 mg at week 0

40 mg

Q2

80 mg Q2 Or 40 mg weekly

80 mg at week 2

Golimumab

200 mg at week 0

50 mg if > 80 kg

Q4

IF < 80 KG Increase to 100 mg

100 mg at week 2

100 mg if > 80 kg

From week 6 (if > 80 kg, N/A)

Vedolizumab

300 mg at weeks 0, 2, & 6

300 mg

Q8

Q4 (Additional Week 10 dose in CD)

Ustekinumab

Week 0.iv:

90 mg SC

Q12 OR Q8

Q8

 < 55 kg 260 mg

55–85 kg 390 mg

 > 85 kg 520 mg

  1. CD Crohn’s disease, IV intravenous; N/A not applicable; SC [62]